Special considerations are provided for managing T2D with comorbid conditions such as cardiovascular disease, chronic kidney disease, hypertension, obesity, and dyslipidemia, emphasizing the pleiotropic benefits of SGLT-2 inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists. The gene discussed is SLC5A2; the disease is chronic kidney disease.